Calidi Biotherapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

CLDI$0.73+4.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Total Equity

CONDENSED CONSOLIDATED STATEMENTS OF TOTAL EQUITY

(Unaudited)

(In thousands, except share amounts)

Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2025	451,076	$—	$145,393	$(13)	$(141,621)	$3,759
Issuance of common stock through March Confidentially Marketed Public Offering, net of financing costs	142,421	—	5,057	—	—	5,057
Exercise of pre-funded warrants	143,188	—	5	—	—	5
Stock-based compensation	—	—	231	—	—	231
Foreign currency translation adjustments	—	—	—	(9)	—	(9)
Net loss	—	—	—	—	(4,108)	(4,108)
Balance at March 31, 2026	736,685	$—	$150,686	$(22)	$(145,729)	$4,935
Issuance of common stock through At the Market Offering	875,656	—	2,200	—	—	2,200
Exercise of pre-funded warrants	470,307	—	5	—	—	5
Stock-based compensation	—	—	157	—	—	157
Foreign currency translation adjustments	—	—	—	(4)	—	(4)
Net loss	—	—	—	—	(4,160)	(4,160)
Balance at June 30, 2026	2,082,648	$—	$153,048	$(26)	$(149,889)	$3,133

Common Stock · Additional Paid-in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ · Non controlling · Total
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity	Interest	Equity
Balance at December 31, 2024	108,166	$—	$123,277	$(28)	$(121,715)	$1,534	$434	$1,968
Issuance of common stock through At the Market Offering	13,980	—	2,754	—	—	2,754	—	2,754
Issuance of common stock and warrants through January Confidentially Marketed Public Offering, net of financing costs	26,042	—	3,607	—	—	3,607	—	3,607
Issuance of common stock and warrants for March Registered Direct Offering and Concurrent Private Placement, net of financing costs	17,318	—	3,423	—	—	3,423	—	3,423
Restricted stock unit shares released	128	—	—	—	—	—	—	—
Stock-based compensation	—	—	607	—	—	607	—	607
Foreign currency translation adjustments	—	—	—	2	—	2	—	2
Net loss	—	—	—	—	(4,986)	(4,986)	(76)	(5,062)
Balance at March 31, 2025	165,634	$—	$133,668	$(26)	$(126,701)	$6,941	$358	$7,299
Exercise of pre-funded warrants	14,209	—	3	—	—	3	—	3
Stock-based compensation	—	—	522	—	—	522	—	522
Foreign currency translation adjustments	—	—	—	13	—	13	—	13
Net loss	—	—	—	—	(5,715)	(5,715)	(46)	(5,761)
Balance at June 30, 2025	179,843	—	134,193	(13)	(132,416)	1,764	312	2,076

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.